Collegium Pharmaceutical (COLL) Stock
Specialty drug maker focused on branded pain relief. Here's the price, business snapshot, and what's worth knowing about Collegium Pharmaceutical in October 2026.
Collegium Pharmaceutical Inc (COLL) is a specialty pharmaceutical company focused on prescription pain therapies, best known for Xtampza ER — an extended‑release oxycodone product with abuse‑deterrent properties. With a market cap around $1.11bn, Collegium generates revenue from branded opioid products and related licensing or distribution arrangements. Key considerations for investors include reliance on a narrow product portfolio, exposure to regulatory scrutiny over opioid prescribing and reimbursement, and potential competition from generics. The company has pursued lifecycle management, patent protection and commercial partnerships to support sales, but future growth depends on market access, prescriber adoption and legal outcomes. Collegium may suit investors seeking exposure to niche pharmaceutical franchises but carries company‑specific and sector risks; this is general information and not personalised investment advice. Values can fall as well as rise, and past performance is not a guide to the future.
Collegium Pharmaceutical (COLL) Stock Forecast
Analyst price target, next 12 months
$46.60
+111.6% vs today's $22.02
Price range over the last 12 months
Close to its 12-month low
Analysts covering Collegium Pharmaceutical have a consensus 12-month target of $46.60, above the current price of $22.02.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Collegium Pharmaceutical's stock with a target price of $46.6, indicating strong growth potential.
Financial Health
Collegium Pharmaceutical is performing well, showing strong profits, cash flow, and revenue growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Product-led growth
Xtampza ER and related branded therapies can support sales growth if prescribing and payer coverage improve, though outcomes depend on uptake and market access.
Regulatory sensitivity
Policy shifts on opioids, approval decisions and label changes can meaningfully affect prospects — regulatory risk is an important watchpoint.
Competition & litigation
Patent protection, generic entrants and past legal disputes have shaped strategy; these factors may influence future revenue and volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
